2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-132821
    Irsenontrine 1429509-82-9 99.91%
    Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases.
    Irsenontrine
  • HY-132907
    MAO-B-IN-2 1253978-24-3 99.05%
    MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC50 values of 0.51 and 7.00 μM, respectively.
    MAO-B-IN-2
  • HY-133024
    Flumexadol 30914-89-7 99.86%
    Flumexadol is a selective and affinity 5-HT2C receptor agonist with a Ki of 25 nM for the (+)-enantiomer of Flumexadol, and is 40-fold selective over the 5-HT2A receptor. Flumexadol is an orally active non-narcotic analgesic.
    Flumexadol
  • HY-133025
    FK962 283167-06-6 99.89%
    FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. Anti-dementia properties.
    FK962
  • HY-133113
    7-Desmethyl-agomelatine 152302-45-9 99.89%
    7-Desmethyl-agomelatine is a metabolite of Agomelatine. Agomelatineis a potent agonist at melatonin receptors (MT1 and MT2), and also is an antagonist of 5-HT2C.
    7-Desmethyl-agomelatine
  • HY-133152
    Brexpiprazole S-oxide 1191900-51-2
    Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM.
    Brexpiprazole S-oxide
  • HY-133486
    GABAA receptor agent 1 1571-87-5 98.93%
    GABAA receptor agent 1 is a high affinity ligand for GABAA receptor, with potent anticonvulsant activity.
    GABAA receptor agent 1
  • HY-133528
    OptoBI-1 2415272-11-4 98%
    OptoBI-1 is a photochromic TRPC3 agonist, which asts as a photopharmacological tool to control of neuronal firing.
    OptoBI-1
  • HY-133712
    Yonkenafil 804518-63-6 99.52%
    Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.
    Yonkenafil
  • HY-133776
    Rivastigmine carbamate impurity 1346242-31-6 99.98%
    Rivastigmine carbamate impurity (3-Nitrophenyl ethyl(methyl)carbamate) is an impurity of Rivastigmine. Rivastigmine is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM, 4.15 μM, respectively.
    Rivastigmine carbamate impurity
  • HY-134145
    1-(Anilinocarbonyl)proline 73096-22-7 99.60%
    1-(Anilinocarbonyl)proline can be used to identify dual action probes in a cell model of Huntington.
    1-(Anilinocarbonyl)proline
  • HY-135006
    Octahydroaminoacridine succinate 866245-79-6 99.88%
    Octahydroaminoacridine succinate, a Tacrine analogue, is an acetylcholinesterse (AChE) and butyrylcholinesterase (BChE) inhibitor. Octahydroaminoacridine succinate can be used for Alzheimer's disease (AD) research.
    Octahydroaminoacridine succinate
  • HY-135230
    LY2444296 1346133-11-6 99.26%
    LY2444296 is an orally bioavailable, high-affinity and selective short-acting kappa opioid receptor (KOPR) antagonist, with a Ki value of ～1 nM. LY2444296 exhibits anti-anxiety like effects.
    LY2444296
  • HY-135608
    BD-1008 138356-08-8 98.41%
    BD-1008 is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM). BD-1008 significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 blocks the self-administration behavior of σ agonists.BD-1008 can be used for the study of addiction therapy that target the σ receptor.
    BD-1008
  • HY-135615
    Desmethyl Sibutramine 168835-59-4 99.45%
    Desmethyl Sibutramine, the secondary metabolite of Sibutramine, is an orally active norepinephrine transporter (NET) and serotonin transporter (SERT) inhibitor. Desmethyl Sibutramine can be used in the research of obesity and appetite suppressant.
    Desmethyl Sibutramine
  • HY-136171
    Antidepressant agent 1 67411-41-0 98.84%
    Antidepressant agent 1 is a pyrazidole-halogeno-derivative with antidepressant effects. Antidepressant agent 1 also can be used to increase body temperature.
    Antidepressant agent 1
  • HY-136922
    Orexin receptor antagonist 2 1457940-75-8 98.08%
    Orexin receptor antagonist 2 (compound 30) is a potent orexin receptor antagonist with pKis of 7.69 and 9.78. Orexin receptor antagonist 2 has the potential for the research of insomnia.
    Orexin receptor antagonist 2
  • HY-137422
    D-erythro-MAPP 143492-38-0 ≥98.0%
    D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro.
    D-erythro-MAPP
  • HY-137459
    Vocacapsaicin 1931116-86-7 98%
    Vocacapsaicin (CA-008), a proagent of Capsaicin, is a first-in-class non-opioid TRPV1 agonist. Vocacapsaicin can provide meaningful and long-lasting pain relief.
    Vocacapsaicin
  • HY-13788C
    LY 344864 racemate 186543-64-6 98.07%
    LY 344864 racemate is a 5-HT1F receptor agonist extracted from patent US 5708187 A.
    LY 344864 racemate
Cat. No. Product Name / Synonyms Application Reactivity